Participants with PVD diagnosed with precapillary PH with right heart catheterization and classified to groups 1 and 4 (PAH or CTEPH) who live in Switzerland will have 6-minute walk distance (6MWD) test with and without nasal liquid oxygen therapy (LOX) approximately 4l/min via nasal cannula according to a randomized cross-over design.
The trial aims to test that the 6MWD with LOX is inferior to a 6MWD in the same participant under ambient air.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\- Minimum 18 years of age
Written informed consent
Patients with diagnosed pulmonary arterial hypertension (PAH), distal chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD) with emphysema, COPD without emphysema, or interstitial lung disease
Former desaturation under exercise defined as SpO2-decrease \>3%
Treated with a stable drug therapy (with no changes for at least 14 days prior to screening)
You may not be if
\- Severe hypoxemia needing supplemental oxygen therapy defined as PaO2 \< 6.9 kPa
Inability or contraindications to undergo the investigated intervention
Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, walk disability etc.
Clareo Health | Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Pulmonary Vascular Disease (PVD)
